A
Alcista
Alcista · 25%APLS
$26.85
Precio del escenario
$41.030
-0.029 (-0.07%)Al cierre
Loading chart…
- Máximo
- 41.070
- Apertura
- 41.050
- Precio medio ponderado por volumen
- 41.04
- Volumen
- 68.61M
- Capitalización
- 5.04B
- Mínimo
- 41.030
- Importe
- 2.82B
- EV/EBITDA, TTM
- 52.52
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Recomendaciones de analistas (3)
-22.76% Potencial de caída
Comprar
3 Comprar
0 Mantener
0 Vender
Actual: 41.03
Mínimo
19.00
Promedio
31.69
Máximo
48.00
Wells Fargo
Equal Weight
$41
2026-04-17
Wells Fargo
2026-04-17
Precio objetivo
$41
Equal Weight
RBC Capital
Sector Perform
$41
2026-04-07
RBC Capital
2026-04-07
Precio objetivo
$41
Sector Perform
Mizuho
Neutral
$41
2026-04-02
Mizuho
2026-04-02
Precio objetivo
$41
Neutral
Roth Capital
Neutral
$41
2026-04-02
Roth Capital
2026-04-02
Precio objetivo
$41
Neutral
JPMorgan
Neutral
$41
2026-04-01
JPMorgan
2026-04-01
Precio objetivo
$41
Neutral
Métricas de valoración
El PER previsto actual de Apellis Pharmaceuticals Inc (APLS) es 46.30, frente a su media de 5 años de -24.84.
Escenarios de precio de Alphio AI para APLS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con APLS en cartera
Cronología de eventos
Noticias
8.506-05stocktwitsPharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
8.505-14GlobenewswireBiogen Completes Acquisition of Apellis Pharmaceuticals
8.505-14NewsfilterBiogen Completes Acquisition of Apellis Pharmaceuticals
4.505-07moomooS&P Dow Jones Indices: Bright Horizons Family Solutions and Remitly Global to be Added to S&P SmallCap 600
4.505-06NASDAQ.COMAnalysis of XBI ETF Trading Dynamics
Preguntas frecuentes sobre APLS, respondidas por Alphio AI
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover APLS: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.69.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.